TESULOID
LOE ApproachingNDAINJECTION, ORALSOLUTION
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESULOID is an older injectable and oral solution approved in 1974 by Bracco with an unknown mechanism of action and pharmacologic class. The drug's specific indications are not documented in available data. This legacy product represents a rare opportunity to work on a well-established compound with decades of real-world use.
LOE Approaching
With LOE approaching and zero linked job postings, this product likely operates as a legacy asset with minimal commercial infrastructure and limited career mobility.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TESULOID presents zero linked job openings and represents a mature, legacy asset with minimal career trajectory. Working on this product would suit early-career professionals seeking stability or those transitioning out of pharma rather than those seeking growth and visibility.
Brand Manager (legacy/maintenance)Field Sales Representative
Worked on TESULOID at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.